Table 1.
Patient Characteristics
| Tacrolimus level at initial steady state | ||||
|---|---|---|---|---|
| <10 ng/mL (N=176) | ≥10 ng/mL (N=34) | Total (N=210) | p value* | |
| Age at HSCT, years | 0.008 | |||
| Median | 52 | 39 | 49 | |
| Range | (4–73) | (8–65) | (4–73) | |
| Recipient sex, n (%) | 0.071 | |||
| Male | 107 (60.8%) | 15 (44.1%) | 122 (58.1%) | |
| Female | 69 (39.2%) | 19 (55.9%) | 88 (41.9%) | |
| Female donor to male recipient, n (%) | 0.31 | |||
| Yes | 31 (17.6%) | 3 (8.8%) | 34 (16.2%) | |
| No | 145 (82.4%) | 31 (91.2%) | 176 (83.8%) | |
| Donor age | 0.68 | |||
| Median | 33 | 32 | 33 | |
| Range | (10–68) | (14–49) | (10–68) | |
| Primary diagnosis HCT, n (%) | 0.023 | |||
| AML | 68 (38.6%) | 10 (29.4%) | 78 (37.1%) | |
| ALL | 35 (19.9%) | 12 (35.3%) | 47 (22.4%) | |
| MDS/CML/MPN | 42 (23.9%) | 2 (5.9%) | 44 (21%) | |
| Lymphoma | 16 (9.1%) | 5 (14.7%) | 21 (10%) | |
| Non-Malignant | 15 (8.5%) | 5 (14.7%) | 20 (9.5%) | |
| DRI, n (%) | 0.32 | |||
| Low | 29 (16.5%) | 2 (5.9%) | 31 (14.8%) | |
| Intermediate | 68 (38.6%) | 13 (38.2%) | 81 (38.6%) | |
| High/Very high | 64 (36.4%) | 14 (41.2%) | 78 (37.1%) | |
| Non-Malignant | 15 (8.5%) | 5 (14.7%) | 20 (9.5%) | |
| Karnofsky performance status %, n (%) | 0.44 | |||
| 80–100 | 146 (83%) | 30 (88.2%) | 176 (83.8%) | |
| <80 | 30 (17%) | 4 (11.8%) | 34 (16.2%) | |
| HCT comorbidity index, n (%) | 0.78 | |||
| 0 | 54 (30.7%) | 12 (35.3%) | 66 (31.4%) | |
| 1–2 | 49 (27.8%) | 10 (29.4%) | 59 (28.1%) | |
| ≥3 | 73 (41.5%) | 12 (35.3%) | 85 (40.5%) | |
| Donor Type | 0.051 | |||
| Haploidentical | 140 (79.5%) | 32 (94.1%) | 172 (81.9%) | |
| Mismatch unrelated | 36 (20.5%) | 2 (5.9%) | 38 (18.1%) | |
| Graft source | <0.001 | |||
| Peripheral Stem Cells | 150 (85.2%) | 16 (47.1%) | 166 (79%) | |
| Bone Marrow | 26 (14.8%) | 18 (52.9%) | 44 (21%) | |
| ABO blood group compatibility, n (%) | 0.76 | |||
| ABO compatible | 116 (65.9%) | 23 (67.6%) | 139 (66.2%) | |
| Minor mismatch (donor is O) | 26 (14.8%) | 6 (17.6%) | 32 (15.2%) | |
| Major mismatch (Recipient is O) | 20 (11.4%) | 4 (11.8%) | 24 (11.4%) | |
| Bidirectional (None are O) | 14 (8%) | 1 (2.9%) | 15 (7.1%) | |
| Donor/Recipient CMV serostatus, n (%) | 0.064 | |||
| D−/R− | 18 (10.2%) | 2 (5.9%) | 20 (9.5%) | |
| D−/R+ | 43 (24.4%) | 4 (11.8%) | 47 (22.4%) | |
| D+/R− | 8 (4.5%) | 5 (14.7%) | 13 (6.2%) | |
| D+/R+ | 107 (60.8%) | 23 (67.6%) | 130 (61.9%) | |
| Conditioning regimen, n (%) | 0.55 | |||
| MAC | 73 (41.5%) | 16 (47.1%) | 89 (42.4%) | |
| TBI-based | 60 (82.2%) | 11 (68.8%) | 71 (79.8%) | |
| Not TBI-based | 13 (17.8%) | 5 (31.3%) | 18 (20.2%) | |
| RIC/NMA | 103 (58.5%) | 18 (52.9%) | 121 (57.6%) | |
| GvHD prophylaxis, n (%) | 1.00 | |||
| PTCy / TAC / MMF | 174 (98.9%) | 34 (100%) | 208 (99%) | |
| PTCy / TAC | 2 (1.1%) | 0 (0%) | 2 (1%) | |
| Year of HCT, n (%) | 0.10 | |||
| ≤2016 | 87 (49.4%) | 22 (64.7%) | 109 (51.9%) | |
| >2016 | 89 (50.6%) | 12 (35.3%) | 101 (48.1%) | |
| Letermovir | 0.081 | |||
| No | 159 (90.3%) | 34 (100%) | 193 (91.9%) | |
| Yes | 17 (9.7%) | 0 (0%) | 17 (8.1%) | |
| Tacrolimus initial dosing method, n (%) | 0.001 | |||
| Flat dose | 118 (67%) | 13 (38.2%) | 131 (62.4%) | |
| Weight base dose | 58 (33%) | 21 (61.8%) | 79 (37.6%) | |
*
P value was based on two-sample Wilcoxon test for age and donor age, Fisher’s exact test or χ2 test for other characteristics.